Biotechnology
Technology
Health
Pacific Biosciences
$7.239876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.11 (-1.50%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell PACB and other stocks, options, ETFs, and crypto commission-free!
About
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. Read More It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Employees
401
Headquarters
Menlo Park, California
Founded
2000
Market Cap
1.10B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.99M
High Today
$7.36
Low Today
$7.20
Open Price
$7.33
Volume
608.62K
52 Week High
$7.84
52 Week Low
$2.44
Collections
Biotechnology
Technology
Health
Software Service
US
North America
News
NasdaqMay 7
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
Pacific Biosciences of California PACB incurred first-quarter 2019 adjusted loss of 20 cents per share, wider than the Zacks Consensus Estimate of a loss of 17 cents.
Seeking AlphaMay 3
Pacific Biosciences of California misses by $0.05, misses on revenue
Pacific Biosciences of California (NASDAQ:PACB): Q1 GAAP EPS of -$0.20 misses by $0.05. Revenue of $16.43M (-15.1% Y/Y) misses by $4.88M . Press Release...
NasdaqMay 3
Pacific Biosciences of California, Inc. Announces First Quarter 2019 Financial Results
MENLO PARK, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its first quarter ended March 31, 2019, as attached. During the first quarter of 2019, the Company announced that it commenced its Early Access Program of the Sequel II System and the SMRT Cell 8M chip with five early access sites. All five early access sites successfully tested the new Sequel II System across a wide variety of customer samples with positive...
Price Paid on Robinhood
46% Higher
Right Now
52 Week Low
$2.44
Average Price Paid
$4.96
52 Week High
$7.84
Earnings
-$0.21
-$0.18
-$0.16
-$0.13
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.15 per share
Actual
-$0.20 per share